All In Biotech

Drug Trial Radar · NCT02367456

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Apr 28, 2015

Primary completion

Jan 29, 2020

Study completion Mar 7, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort.

Conditions

  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia

Interventions

  • PF-04449913 (Glasdegib)Drug

    Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles

  • AzacitidineDrug

    75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Lead-in Cohort (LIC)Time frame: maximum of approximately 15 months
  2. Number of Participants With Serious Adverse Events (SAEs) in the LICTime frame: maximum of approximately 15 months
  3. Number of Participants With Laboratory Abnormalities in the LICTime frame: maximum of approximately 16 months
  4. Percentage of Participants Achieving Complete Remission (CR) in the AML and MDS CohortsTime frame: maximum of 23 months in AML cohort and 34 months in MDS cohort

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham the Kirklin Clinic

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Smilow Cancer Center at Yale New Haven Hospital

    New Haven, Connecticut

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Stony Brook University Hospital Cancer Center

    Stony Brook, New York

  • Stony Brook University

    Stony Brook, New York

  • Montefiore Einstein Center for Cancer

    The Bronx, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Health System: Adult Bone Marrow Transplant Clinic

    Durham, North Carolina

  • Duke University Health System, Duke University Hospital

    Durham, North Carolina

  • Duke University Health System

    Durham, North Carolina

  • Investigational Chemotherapy Service

    Durham, North Carolina

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • Henry-Joyce Cancer Center

    Nashville, Tennessee

  • Vanderbilt - Ingram Cancer Center

    Nashville, Tennessee

  • Huntsman Cancer Hospital

    Salt Lake City, Utah

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance (SCCA)

    Seattle, Washington

  • University of Washington Medical Center (UWMC)

    Seattle, Washington

  • Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg

    Antwerp, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Tom Baker Cancer Center

    Calgary, Alberta, Canada

  • University Of Alberta Hospital

    Edmonton, Alberta, Canada

  • CHU d'Amiens-Picardie - Hopital SUD

    Amiens, France

  • Hopital Saint-Louis (AP-HP) - Service Hematologie Senior

    Paris, France

  • Hospices Civils de Lyon - Hopital Lyon Sud- Hematologie

    Pierre-Bénite, France

  • CHU de Tours-Hopital Bretonneau-Centre Regional de cancerologie Henry Kaplan

    Tours, France

  • Staedtisches Klinikum Braunschweig gGmbH

    Braunschweig, Germany

  • King's College Hospital

    London, United Kingdom

  • The Newcastle Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.